Cargando…

Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement

RATIONALE: Prostate cancer treatment response may be automatically quantified using a molecular imaging analysis platform targeting prostate-specific membrane antigen (PSMA). METHODS: A retrospective analysis of patients with castration-sensitive prostate cancer who underwent PSMA-targeted molecular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duriseti, Sai, Berenji, Gholam, Tsai, Sonny, Rettig, Matthew, Nickols, Nicholas G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068685/ https://www.ncbi.nlm.nih.gov/pubmed/37009941 http://dx.doi.org/10.1186/s41824-023-00165-6

Ejemplares similares

PSMA-PET Detection of Unusual Metastases in Castrate-Sensitive Prostate Carcinoma
por: Harris, Nathanial, et al.
Publicado: (2023)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018)

Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET
por: McGeorge, Stephen, et al.
Publicado: (2021)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Isolated, PSMA-negative penile metastasis from castration resistant prostate adenocarcinoma, identified by FDG-PET
por: Chau, Matthew, et al.
Publicado: (2022)

Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting
por: Johnsson, Kerstin, et al.
Publicado: (2021)

PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study
por: Mattoni, Susanna, et al.
Publicado: (2022)

False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial
por: Fendler, Wolfgang P., et al.
Publicado: (2020)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study
por: Sonni, Ida, et al.
Publicado: (2023)

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
por: Bergamini, Marco, et al.
Publicado: (2022)

Isolated Castrate-resistant Prostate Cancer Metastasis to Both Adrenal Glands Detected on (68)Ga PSMA PET/CT
por: Kanatsız, Osman, et al.
Publicado: (2023)

(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Sanli, Yasemin, et al.
Publicado: (2021)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Predictive and prognostic potential of pretreatment (68)Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
por: Assadi, Majid, et al.
Publicado: (2022)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
por: Gafita, Andrei, et al.
Publicado: (2022)

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
por: Calais, Jeremie, et al.
Publicado: (2021)

PSMA-PET in the early stages of prostate cancer
por: Barbosa, Felipe de Galiza
Publicado: (2023)

A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer Patients
por: Serani, Francesca, et al.
Publicado: (2023)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
por: Cereser, Lorenzo, et al.
Publicado: (2023)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
por: Leung, Kevin H., et al.
Publicado: (2022)

FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer
por: Kichloo, Asim, et al.
Publicado: (2020)

Clinical Translation and First In-Human Use of [(44)Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer
por: Eppard, Elisabeth, et al.
Publicado: (2017)

Clinical perspectives of PSMA PET/MRI for prostate cancer
por: Barbosa, Felipe de Galiza, et al.
Publicado: (2018)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

PSMA PET imaging in the diagnosis and management of prostate cancer
por: Houshmand, Sina, et al.
Publicado: (2023)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
por: Gaudreault, Mathieu, et al.
Publicado: (2023)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

The Impact of (18)F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [(177)Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
por: Stangl-Kremser, Judith, et al.
Publicado: (2021)

Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer
por: Rasul, Sazan, et al.
Publicado: (2022)

Irreversible electroporation for prostate cancer using PSMA PET-CT
por: Shin, Dongho, et al.
Publicado: (2023)

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Juzeniene, Asta, et al.
Publicado: (2021)

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
por: Giraudet, Anne-Laure, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1fhcqmg1uh1v3gs7p7u3kqaha2